Information Provided By: 
Fly News Breaks for January 27, 2016
SCMP
Jan 27, 2016 | 09:11 EDT
After Sucampo paid $10M for an exclusive option on Cancer Prevention Pharmaceuticals' Phase 3 asset, CPP-1X/Sulindac, a combination therapy for familial adenomatous polyposis. Roth Capital says the deal "has relatively low clinical risk and impressive revenue potential." Roth says that the drug combination has "demonstrated impressive reductions in colorectal adenoma recurrence (70%), multiple adenomas (95%) and advanced adenomas (90%) versus placebo." It keeps a Buy rating on Sucampo.
News For SCMP From the Last 2 Days
There are no results for your query SCMP
